4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 89 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $23,173 | -60.9% | 1,104 | -40.6% | 0.00% | – |
| Q1 2024 | $59,260 | +62.8% | 1,860 | +3.5% | 0.00% | – |
| Q4 2023 | $36,407 | +983.2% | 1,797 | +580.7% | 0.00% | – |
| Q3 2023 | $3,361 | -29.5% | 264 | 0.0% | 0.00% | – |
| Q2 2023 | $4,770 | +90.0% | 264 | +133.6% | 0.00% | – |
| Q4 2022 | $2,510 | -16.3% | 113 | -69.6% | 0.00% | – |
| Q3 2022 | $3,000 | -40.0% | 372 | -48.6% | 0.00% | – |
| Q2 2022 | $5,000 | -76.2% | 724 | -48.4% | 0.00% | – |
| Q1 2022 | $21,000 | +31.2% | 1,404 | +98.0% | 0.00% | – |
| Q4 2021 | $16,000 | +77.8% | 709 | +123.0% | 0.00% | – |
| Q3 2021 | $9,000 | – | 318 | +1490.0% | 0.00% | – |
| Q2 2021 | $0 | – | 20 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VR Adviser, LLC | 4,400,000 | $92,356,000 | 5.88% |
| Deep Track Capital, LP | 4,061,401 | $85,248,807 | 2.54% |
| BVF INC/IL | 3,922,413 | $82,331,449 | 2.31% |
| Decheng Capital LLC | 347,835 | $7,301,057 | 2.24% |
| Novo Holdings A/S | 1,400,000 | $29,386,000 | 1.71% |
| Eagle Health Investments LP | 462,911 | $9,716,502 | 1.70% |
| Opaleye Management Inc. | 345,750 | $7,257,293 | 1.66% |
| RA Capital Management | 5,098,211 | $107,011,449 | 1.42% |
| Redmile Group, LLC | 1,073,435 | $22,531,401 | 1.36% |
| Casdin Capital, LLC | 800,000 | $16,792,000 | 1.29% |